Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals ARWR Stock

$42.99   -2.759551%
Add to favorites
Market Cap
$6.08B
LOW - HIGH [24H]
$42.07 - $44.55
VOLUME [24H]
$3.70M
P/E Ratio
0
Earnings per share
-$5.11
ISIN
US04280A1007
Price   Prediction

Arrowhead Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

Arrowhead Pharmaceuticals (ARWR) stock price today is 42.99 USD on Tech Market Large (-2.76% on the day). Updated .

Arrowhead Pharmaceuticals ARWR Financial and Trading Overview

Arrowhead Pharmaceuticals stock price 42.99 USD
Previous Close 47.78 USD
Open 47.12 USD
Bid 40.95 USD x 200
Ask 48.36 USD x 200
Day's Range 44.07 - 47.41 USD
52 Week Range 37.06 - 95.49 USD
Volume 1.86M USD
Avg. Volume 1.94M USD
Market Cap 6.25B USD
Beta (5Y Monthly) 1.368
PE Ratio (TTM) N/A
EPS (TTM) -5.11 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 106.07 USD

ARWR Valuation Measures

Enterprise Value 6.47B USD
Trailing P/E N/A
Forward P/E -13.568967
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 13.86345
Price/Book (mrq) 124.18539
Enterprise Value/Revenue 14.349
Enterprise Value/EBITDA -9.505

Trading Information

Arrowhead Pharmaceuticals Stock Price History

Beta (5Y Monthly) 1.368
52-Week Change 19.00%
S&P500 52-Week Change 13.32%
52 Week High 95.49 USD
52 Week Low 37.06 USD
50-Day Moving Average 63.32 USD
200-Day Moving Average 71.09 USD

ARWR Share Statistics

Avg. Volume (3 month) 1.94M USD
Avg. Daily Volume (10-Days) 2.59M USD
Shares Outstanding 141.37M
Float 122.56M
Short Ratio 6.68
% Held by Insiders 3.86%
% Held by Institutions 85.42%
Shares Short 11.58M
Short % of Float 11.39%
Short % of Shares Outstanding 8.19%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:10

Financial Highlights

Fiscal Year

Fiscal Year Ends September 30, 2026
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End September 30, 2027

Profitability

Profit Margin -160.64%
Operating Margin (ttm) -156.86%
Gross Margin 99.60%
EBITDA Margin -150.95%

Management Effectiveness

Return on Assets (ttm) -28.29%
Return on Equity (ttm) -258.93%

Income Statement

Revenue (ttm) 450.82M USD
Revenue Per Share (ttm) 3.18 USD
Quarterly Revenue Growth (yoy) -85.29%
Gross Profit (ttm) 449.02M USD
EBITDA -680548992 USD
Net Income Avi to Common (ttm) -724206016 USD
Diluted EPS (ttm) -5.11
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 1.19B USD
Total Cash Per Share (mrq) 8.41 USD
Total Debt (mrq) 1.41B USD
Total Debt/Equity (mrq) 2786.66 USD
Current Ratio (mrq) 4.141
Book Value Per Share (mrq) 0.356

Cash Flow Statement

Operating Cash Flow (ttm) -271948992 USD
Levered Free Cash Flow (ttm) -586995392 USD

Profile of Arrowhead Pharmaceuticals

Country United States
State CA
City Pasadena
Address 177 East Colorado Boulevard
ZIP 91105
Phone 626 304 3400
Website https://arrowheadpharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 1062

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Q&A For Arrowhead Pharmaceuticals Stock

What is a current ARWR stock price?

Arrowhead Pharmaceuticals ARWR stock price today per share is 42.99 USD.

How to purchase Arrowhead Pharmaceuticals stock?

You can buy ARWR shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Arrowhead Pharmaceuticals?

The stock symbol or ticker of Arrowhead Pharmaceuticals is ARWR.

Which industry does the Arrowhead Pharmaceuticals company belong to?

The Arrowhead Pharmaceuticals industry is Biotechnology.

How many shares does Arrowhead Pharmaceuticals have in circulation?

The max supply of Arrowhead Pharmaceuticals shares is 141.37M.

What is Arrowhead Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Arrowhead Pharmaceuticals PE Ratio is now.

What was Arrowhead Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Arrowhead Pharmaceuticals EPS is -5.11 USD over the trailing 12 months.

Which sector does the Arrowhead Pharmaceuticals company belong to?

The Arrowhead Pharmaceuticals sector is Healthcare.

Arrowhead Pharmaceuticals ARWR included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24328.38 USD —
-0.74
8.59B USD — 23989.09 USD — 24547.66 USD — — 8.59B USD —
us US Tech Global Select Market Com NQGS US 11984.26 USD —
-0.73
— — 11815.78 USD — 12090.12 USD — — — —
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
— — 2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD — — —
us US Tech Biotechnology NBI US 7017.81 USD —
-0.71
— — 6949.3 USD — 7058.02 USD — — — —
us US Tech Health Care IXHC US 1332.89 USD —
-0.73
— — 1323.81 USD — 1342.94 USD — — — —
us US Tech Composite Total Return XCMP US 30064.18 USD —
-0.74
— — 29644.9 USD — 30335.16 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3623.52 USD —
-1.17
— — 3590.07 USD — 3671.9 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Biotechnology Total Retu XNBI US 7668.49 USD —
-0.71
— — 7593.62 USD — 7712.43 USD — — — —
$2.22T
Total marketcap
$79.85B
Total volume
BTC 58.41%   •   ETH 9.97%
Dominance
Select currency